检索结果-南通市图书馆

Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第4期21卷 1189-1196页

作者： Christopher Leung Sern Wei Yeoh desmond Patrick Shara Ket Kaye Marion Paul Gow peter W Angus Liver Transplant Unit Austin HospitalHeidelbergVictoria 3084Australia Department of Medicine The University of MelbourneAustin CampusHeidelbergVictoria 3084Australia Statistics and Operations Research Group School of Mathematical and Geospatial Sciences College of ScienceEngineering and HealthRMIT UniversityMelbourneVictoria 3000Australia

AIM: To determine characteristics and prognosticpredictors of patients with hepatocellular carcinoma(HCC) in association with non-alcoholic fatty liver disease(NAFLD).METHODS: We reviewed the records of all patients with NAFLD associated HCC between 2000 and 2012. Data collected included demographics; histology; presence or absence of cirrhosis, size and number of HCC, alpha-fetoprotein, body mass index(BMI), and the presence of diabetes, hypertension, or ***: Fifty-four patients with NAFLD associated HCC were identified. Mean age was 64 years with 87% male. Fifteen percent(8/54) were not cirrhotic. 11%, 24% and 50% had a BMI of < 25 kg/m2, 25-29 kg/m2 and ≥ 30 kg/m2 respectively. Fifty-nine percent were diabetic, 44% hypertensive and 26% hyperlipidaemic. Thirty-four percent of the patients had ≤ 1 of these risk factors. Non-cirrhotics had a significantly larger mean tumour diameter at diagnosis than cirrhotics(P = 0.041). Multivariate analysis did not identify any other patient characteristics that predicted the size or number of ***: HCC can develop in NAFLD without cirrhosis. At diagnosis such tumours are larger than those in cirrhotics, conferring a poorer prognosis.

关键词： Hepatocellular carcinoma Non-alcoholic fatty liver

Cost-effectiveness of Crohn's disease post-operative care

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第14期22卷 3860-3868页

作者： Emily K Wright Michael A Kamm peter Dr Cruz Amy L Hamilton Kathryn J Ritchie Sally J Bell Steven J Brown William R Connell Paul V desmond Danny Liew Department of Gastroenterology St Vincent's Hospital University of Melbourne Fitzroy VIC 3065 Melbourne Australia Imperial College London SW7 2AZ United Kingdom Melbourne EpiCentre University of Melbourne and Melbourne Health Parkville VIC 3010 Melbourne Australia

AIM: To define the cost-effectiveness of strategies, including endoscopy and immunosuppression, to prevent endoscopic recurrence of Crohn’s disease following intestinal ***: In the “POCER” study patients undergoing intestinal resection were treated with post-operative drug therapy. Two thirds were randomized to active care (6 mo colonoscopy and drug intensification for endoscopic recurrence) and one third to drug therapy without early endoscopy. Colonoscopy at 18 mo and faecal calprotectin (FC) measurement were used to assess disease recurrence. Administrative data, chart review and patient questionnaires were collected prospectively over 18 ***: Sixty patients (active care n = 43, standard care n = 17) were included from one health service. Median total health care cost was $6440 per patient. Active care cost $4824 more than standard care over 18 mo. Medication accounted for 78% of total cost, of which 90% was for adalimumab. Median health care cost was higher for those with endoscopic recurrence compared to those in remission [$26347 (IQR 25045-27485) vs $2729 (IQR 1182-5215), P < 0.001]. FC to select patients for colonoscopy could reduce cost by $1010 per patient over 18 mo. Active care was associated with 18% decreased endoscopic recurrence, costing $861 for each recurrence ***: Post-operative management strategies are associated with high cost, primarily medication related. Calprotectin use reduces costs. The long term cost-benefit of these strategies remains to be evaluated.

关键词： Crohn’ s disease Post-operative Health economics Health care cost Biologics

Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第17期21卷 5352-5358页

作者： Aflah Roohullah Hui-Li Wong Katrin M Sjoquist peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill Macarthur Cancer Therapy Centre CampbelltownNSW 2560Australia NHMRC Clinical Trials Centre CamperdownNSW 2050Australia Department of Medical Oncology Royal Melbourne HospitalParkvilleVIC 3052Australia Melbourne Medical School University of MelbourneMelbourneVIC 3000Australia Department of Medical Oncology Box Hill HospitalBox HillVIC 3128Australia St George Cancer Care Centre KogarahNSW 2217Australia Department of Medical Oncology Western HospitalFootscrayVIC 3011Australia Department of Medical Oncology Cabrini HealthMelbourneVIC 3000Australia Department of Medical Oncology the Canberra HospitalGarranACT 2605Australia ANU Medical School Australia National UniversityCanberraACT 2600Australia Department of Medical Oncology Royal Hobart HospitalHobartTAS 7000Australia Liverpool Cancer Therapy Centre LiverpoolNSW 2170Australia Department of Medical Oncology the Queen Elizabeth HospitalWoodvilleSA 5011Australia Department of Medical Oncology Austin HealthHeidelbergVIC 3084Australia the Kinghorn Cancer Centre Garvan Institute of Medical ResearchDarlinghurstNSW 2010Australia

AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal ***:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal *** endpoints included progression-free survival,chemotherapy duration,and overall ***-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank ***:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal *** were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC *** the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone *** the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone *** a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal p

关键词： Peritoneal neoplasms Colorectal neoplasms Bevacizumab Intestinal perforation Capecitabine

至尊——阿联酋迪拜酋长皇宫酒店，绵延1．3km的真正皇家体验

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

照明设计 2006年第3期 60-67页

作者： David Robertson desmond O＇Donovan peter Fordham Dorothea Schmid（摄影） Emirates Palace（摄影）马艳（译）

酋长皇宫酒店隶属于Kempinski旅店鞋号，并且被认为是世界上最大、最豪华的酒店之一。2005年2月酒店铺开了红地毯，欢迎客人入住。由于“五星级”显得远远不足以标榜这个华贵的处所，干脆就将“皇宫”一词冠在酒店名前。客人被带入一个... 详细信息

酋长皇宫酒店隶属于Kempinski旅店鞋号，并且被认为是世界上最大、最豪华的酒店之一。2005年2月酒店铺开了红地毯，欢迎客人入住。由于“五星级”显得远远不足以标榜这个华贵的处所，干脆就将“皇宫”一词冠在酒店名前。客人被带入一个不可思议的世界，那里洋溢着浪漫、妙想与奇遇，浸淫在国王般的奢华中。奢华常与黄金相伴，特别是在阿拉伯世界中。伦敦的DHA做的照明设计更为其平添了一份魅力。

关键词：酒店皇宫阿联酋迪拜照明设计世界五星级阿拉伯

社交网络数据分析中的数学概念、方法及其应用

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

数学译林 2012年第1期31卷 15-22页

作者： desmond J. Higham peter Grindrod Ernesto Estrada 叶其孝(译) 吴庆宝(校)

在迅速发展的网络科学领域中的许多关键思想可以追溯到20世纪50和60年代，那时研究人员开始细化社会相互作用的研究．数学的语言和工具，特别是图论和线性代数提供了很自然的研究框架，很快数学家就把社交网络分析作为一种切实可行的应... 详细信息

在迅速发展的网络科学领域中的许多关键思想可以追溯到20世纪50和60年代，那时研究人员开始细化社会相互作用的研究．数学的语言和工具，特别是图论和线性代数提供了很自然的研究框架，很快数学家就把社交网络分析作为一种切实可行的应用领域，

关键词：数学概念网络科学数据分析社交应用相互作用研究人员线性代数

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

改编的艺术

双肺通气时混合吸入空气可延迟单肺通气时的肺萎陷

作者： (美)约翰·M. 德斯蒙德(John M. desmond) (美)彼得·霍克斯(peter Hawkes)

来源：南通市图书馆图书评论

学校读者我要写书评

暂无评论

麻醉与镇痛 2011年第3期7卷 61-65页

作者： Raynauld Ko, MD Karen McRae, MDCM Gail Darling, MD Thomas K. Waddell MD, PhD desmond McGlade, MBBS, FANZCA Ken Cheung, MD Joel Katz, PhD peter Slinger, MD 刘晓(译) Departments of Anesthesia and Pain Management University Health Network University of Toronto Ontario Canada Surgery Division of Thoracic Surgery Toronto General Hospital University Health Network University of Toronto Ontario Canada 不详

背景一侧肺萎陷有助于显露胸外科手术的手术野。双肺通气时吸入不同的混合气体可通过加速或延迟肺萎陷过程，从而改善或影响单肺通气时的手术条件。我们观察了双肺通气时吸入3种不同的混合气体对单肺通气时肺萎陷和氧合的影响：空气／... 详细信息

背景一侧肺萎陷有助于显露胸外科手术的手术野。双肺通气时吸入不同的混合气体可通过加速或延迟肺萎陷过程，从而改善或影响单肺通气时的手术条件。我们观察了双肺通气时吸入3种不同的混合气体对单肺通气时肺萎陷和氧合的影响：空气／氧气（FiO2=0．4）、氧化亚氮（N2O）／氧气（FiO2=0．4）、氧气（FiO2=1．0）。方法将受试者随机分为3组：空气／氧气组（n=33）、N2O组（n=34）和O2组（n=33），麻醉诱导时吸入不同的混合气体直至开始单肺通气。在单肺通气过程中所有受试者的FiO2均为1．0。手术者不参与分组，并在单肺通气开始后10和20分钟的时间点用口头量表评价肺萎陷的程度。在麻醉诱导前、双肺通气时以及单肺通气后的30分钟内每5分钟查一次动脉血气。结果双肺通气时混合吸入空气可延迟单肺通气时的肺萎陷，而混合吸入氧化亚氮则可加速肺萎陷。O2组的动脉氧合仅在单肺通气开始10分钟内显著改善，之后各组间的平均PaO2差异无显著性。结论双肺通气时去除肺内的氮气是改善单肺通气时手术条件的一项重要策略。双肺通气时使用FiO2=1．0或N2O／O2（FiO2=0．4）时，对单肺通气的氧合并没有明显的不利影响。

关键词：单肺通气双肺通气肺萎陷空气吸入氧化亚氮混合气体 FiO2 动脉氧合

Strategies for PET imaging of the receptor for advanced glycation endproducts(RAGE)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Pharmaceutical Analysis 2020年第5期10卷 452-465页

作者： Lindsey R.Drake Allen F.Brooks Jenelle Stauff Phillip S.Sherman Janna Arteaga Robert A.Koeppe Aimee Reed Timothy J.Montavon Marc B.Skaddan peter J.H.Scott Department of Radiology University of MichiganAnn ArborMI48109USA Department of Medicinal Chemistry University of MichiganAnn ArborMI48109USA AbbVie Process Chemistry North ChicagoIL60064USA AbbVie Centralized Medicinal Chemistry North ChicagoIL60064USA AbbVie Translational Imaging North ChicagoIL60064USA

The implication of the receptor for advanced glycation end-products(RAGE)in numerous diseases and neurodegenerative disorders makes it interesting both as a therapeutic target and as an inflammatory *** the context of investigating RAGE as a biomarker,there is interest in developing radiotracers that will enable quantification of RAGE using positron emission tomography(PET)*** have synthesized potential small molecule radiotracers for both the intracellular([18F]InRAGER)and extracellular([18F]RAGER)domains of *** we report preclinical evaluation of both using in vitro(lead panel screens)and in vivo(rodent and nonhuman primate PET imaging)*** radiotracers have high affinity for RAGE and show good brain uptake,but suffer from off-target *** source of the off-target PET signal is not attributable to binding to melatonin receptors,but remains *** have also investigated use of lipopolysaccharide(LPS)-treated mice as a possible animal model with upregulated RAGE for evaluation of new imaging *** of the mouse brain sections revealed increases in RAGE in the male cohorts,but no difference in the female ***,it proves challenging to quantify the changes in RAGE due to off-target binding of the ***,they are appropriate lead scaffolds for future development of 2nd generation RAGE PET radiotracers because of their high affinity for the receptor and good CNS penetration.

关键词： RAGE Neuroimaging Positron emission tomography Radiochemistry Neuroinflammation

CEPC Technical Design Report

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise